Science Saturday: Z-Endoxifen emerges as potential breast cancer treatment
Summary Results of a phase I study in women showed that the treatment was safe and reduced tumors. Z-endoxifen, a potent derivative of the drug?tamoxifen, could be a new treatment for the most common form of breast cancer in women with metastatic disease. This finding was reported from a clinical trial conducted by researchers at [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - April 21, 2018 Category: Databases & Libraries Source Type: news
Tamoxifen and raloxifene slow down the progression of muscular dystrophy
(Elsevier) Steroids are currently the only available treatment to reduce the repetitive cycles of inflammation and disease progression associated with functional deterioration in patients with muscular dystrophy (MD). A study reported in The American Journal of Pathology showed that a new treatment approach using the selective estrogen receptor modulators (SERMs) tamoxifen and raloxifene significantly improved cardiac, respiratory, and skeletal muscle functions and increased bone density in both male and female mice with the same gene defects as a subset of patients with MD. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 20, 2018 Category: Biology Source Type: news
New international practice guidelines for tamoxifen treatment based on CYP2D6 genotype
(Mayo Clinic) An international group of clinicians and scientists representing the Clinical Pharmacogenetics Implementation Consortium (CPIC) published the first-ever clinical practice guideline for using CYP2D6 genotype to guide tamoxifen therapy in Clinical Pharmacology and Therapeutics. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 1, 2018 Category: Cancer & Oncology Source Type: news
Medical News Today: Can weight gain be caused by tamoxifen?
A look at the link between tamoxifen and weight gain. Included is detail on why weight gain can occur in breast cancer treatment, and other side effects. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 22, 2018 Category: Consumer Health News Tags: Breast Cancer Source Type: news
Novartis Kisqali ® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer
Novartis today announced Kisqali® (ribociclib) received US Food and Drug Administration (FDA) Breakthrough Therapy designation for initial endocrine-based treatment of pre- or perimenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer in combination with tamoxifen or an aromatase inhibitor. (Source: World Pharma News)
Source: World Pharma News - January 3, 2018 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news
JACQUIE BELTRAO on her tamoxifen living hell
Tamoixifen might be a lifesaver for breast cancer patients, but it's irritating side effects, such as late night hot flushes, are absolutely awful, writes Sky News' JACQUIE BELTRAO. (Source: the Mail online | Health)
Source: the Mail online | Health - December 17, 2017 Category: Consumer Health News Source Type: news
Breast cancer can return 20 years after first diagnosis
The disease can ‘lie dormant’ for years, reappearing long after patients get all-clear, say Oxford University researchers. Women may be told to continue drugs like tamoxifen for longer. (Source: the Mail online | Health)
Source: the Mail online | Health - November 8, 2017 Category: Consumer Health News Source Type: news
Risk of Uterine Diseases, Cancers Up With Tamoxifen Treatment
After adjustment for confounding variables, risk of endometrial cancer was increased almost fourfold with tamoxifen treatment (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 12, 2017 Category: Cancer & Oncology Tags: Gynecology, Internal Medicine, Oncology, Pharmacy, Journal, Source Type: news
Z-endoxifen shows promise as new treatment for common breast cancer type
(Mayo Clinic) ROCHESTER, Minn. - Z-endoxifen, a potent derivative of the drug tamoxifen, could itself be a new treatment for the most common form of breast cancer in women with metastatic disease. This finding was reported from a clinical trial conducted by researchers at Mayo Clinic and the National Cancer Institute, and published in the Journal of Clinical Oncology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 30, 2017 Category: International Medicine & Public Health Source Type: news
Z-endoxifen shows promise as new treatment for common breast cancer type
ROCHESTER, Minn. ??Z-endoxifen, a potent derivative of the drug tamoxifen, could itself be a new treatment for the most common form of breast cancer in women with metastatic disease. This finding was reported from a clinical trial conducted by researchers at Mayo Clinic and the National Cancer Institute, and published in the Journal of [...] (Source: Mayo Clinic Minnesota News)
Source: Mayo Clinic Minnesota News - August 30, 2017 Category: Hospital Management Source Type: news
Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer
This video highlights trials studying the long-term impact of adjuvant tamoxifen and aromatase inhibitors for the treatment of patients with postmenopausal breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - August 25, 2017 Category: Cancer & Oncology Authors: Prudence A. Francis, MD Tags: Videos Breast Cancer Source Type: news
Breast cancer wonder drug boosts IVF hopes
A British clinic is pioneering the use of tamoxifen - typically given to patients who have undergone breast cancer surgery - to help women aged over 40 who have a limited number of eggs. (Source: the Mail online | Health)
Source: the Mail online | Health - August 13, 2017 Category: Consumer Health News Source Type: news
Gene Score for Recurrence Risk in ER-Positive Breast Cancer Gene Score for Recurrence Risk in ER-Positive Breast Cancer
Can this gene recurrence score help determine which patients with ER-positive breast cancer are good candidates for radiotherapy after adjuvant chemotherapy plus tamoxifen?Journal of the National Cancer Institute (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 20, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
RCT: Menopause Symptoms Mistaken for Tamoxifen Side Effects RCT: Menopause Symptoms Mistaken for Tamoxifen Side Effects
Many women who use tamoxifen as a chemopreventive agent experience symptoms that are assumed to be drug related, but they may just be naturally occurring symptoms related to menopause.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 6, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
